An observational study in Carcinoma, Non-small-cell Lung Cancer and Lung Neoplasms, sponsored by Peking University People's Hospital. Status unknown at 3 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-05-21.
Sponsored by Peking University People's Hospital · Observational
Conduct a prospective study to confirm blood and urine ctDNA detection value in non-small-cell lung cancer patients.
Studies have shown the feasibility of detecting mutation status by blood and urine circulating tumor DNA (ctDNA)in non-small cell lung cancer (NSCLC) patients. However, no prospective has been conducted for usage of ctDNA in postoperative surveillance of NSCLC patients.
We plan to compare tumor makers and radiographic approaches with blood and urine ctDNA in surveillance to assess the lead time of postoperative tumor relapse in stage ⅢA NSCLC patients. And evaluate the correlation between ctDNA level with tumor relapse or metastasis.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's planned enrollment of 145 is below the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Peking University People's Hospital is the lead sponsor of 584 studies on the registry; 233 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Histologically confirmed stage ⅢA non-small cell lung cancer patients who have the same driver mutation in tumor tissue and circulating tumor DNA(blood or urine)
Exclusion Criteria:
Lead time of tumor relapse detection by blood or urine circulation tumor DNA than radiographic approaches
Time frame: 4 years
Lead time of tumor relapse detection by blood or urine circulation tumor DNA than tumor markers
Time frame: 4 years
The concordance of ctDNA genomic alterations detection in peripheral blood and urine with those in matched tumor sample
Time frame: 1 year
Correlation of blood and urine ctDNA concentration before surgery with clinical features and prognosis
Time frame: 4 years
Correlation of blood and urine ctDNA concentration 3 days after surgery with clinical features and prognosis
Time frame: 4 years
CtDNA predictive value between locoregional recurrence and distant metastasis
Time frame: 4 years
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University People's Hospital